The agreement will integrate a specific antibody into diagnostic tests for use on widely installed immunoassay systems.
ALZpath Inc. announced a global licensing agreement with Abbott to incorporate its proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer’s disease. The test is designed for use on Abbott’s Alinity ci-series systems.
The ALZpath pTau217 antibody is used to detect Alzheimer’s disease pathology and has been featured in more than 200 peer-reviewed publications across 18 countries, according to a press release from the company, which notes the antibody demonstrates high sensitivity and accuracy in identifying the biology of the disease.
“This agreement further strengthens ALZpath’s leadership in blood-based Alzheimer’s testing and reinforces our position as the foundational component supporting the overwhelming majority of the pTau217 IVD market,” says Mike Banville, CEO of ALZpath, in a release. “As blood-based biomarkers become central to how Alzheimer’s disease is detected and managed, partnering with a global healthcare leader like Abbott can enable high-performance testing to reach clinicians and patients around the world at scale.”
As disease-modifying therapies for Alzheimer’s continue to expand, blood-based biomarkers offer a scalable alternative to positron emission tomography imaging and cerebrospinal fluid analysis. These traditional methods can be invasive, costly, and difficult to deploy at scale, according to the release. Blood-based biomarkers may also play a role in monitoring how the disease progresses and how patients respond to treatment in routine clinical settings.
“Collaborations like this are accelerating the next era of Alzheimer’s disease research, clinical trials for therapies, and ultimately patient care,” says John Frels, vice president of research and development in Abbott’s Core Diagnostics business, in a release.
ALZpath says it remains focused on bringing the antibody into routine care, including primary care settings, to reach more patients in need.
ID 294234508 © Skypixel | Dreamstime.com
